Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00985530CT.gov Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | — | Terminated | — | — | — |
NCT00520208CT.gov Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Promyelocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tamibarotene (this asset) | Northwestern University | P2 | CCC · 50 |
| Tretinoin | The Affiliated People's Hospital of Ningbo University | P4 | BBB |
| Cytarabine | Associazione Italiana Ematologia Oncologia Pediatrica | P4 | BBB |
| Idarubicin | Technische Universität Dresden | P4 | BBB |
| Arsenic Trioxide | Quetzal Therapeutics | P4 | BBB |
| Methotrexate | Technische Universität Dresden | P3 | BBB |
| Mitoxantrone | Technische Universität Dresden | P4 | BBB |
| Daunomycin | Peking University People's Hospital | P4 | BB |
| Cyclosporin A | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Acute Promyelocytic Leukemia cohort
Other indications for Tamibarotene
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 46 |
| Myelodysplastic Syndrome | — | P2 | CC · 43 |
| Alzheimer Disease | — | P2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tamibarotene in Acute Promyelocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tamibarotene-acute-promyelocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →